Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Systemic Aspergillosis And Systemic Candidiasis Market Growth in 2025?

In the past few years, there has been a steady increase in the market size of systemic aspergillosis and systemic candidiasis. The market, which was valued at $7.24 billion in 2024, is estimated to increase to $7.59 billion by 2025, with a compound annual growth rate (CAGR) of 4.8%. The factors contributing to this historic growth include a rise in fungal infections, a growing population of patients with compromised immune systems, advancements in diagnostic technologies, an increase in invasive medical procedures, and a worldwide transmission of infections.

What Is the Forecast for the Systemic Aspergillosis And Systemic Candidiasis Market Size Through 2029?

The market for systemic aspergillosis and systemic candidiasis is projected to experience significant expansion in the forthcoming years. The market worth is expected to reach $9.28 billion by 2029, growing at a compound annual growth rate of 5.1%. The predicted growth in this timeframe can be credited to worldwide observation of antifungal resistance, an aging demographic, the use of telemedicine for remote patient consultations, patient-focused medication development, and digital health solutions for patient care. Major forthcoming trends include the discovery of new fungal biomarkers for early diagnosis, the development of innovative antifungal drugs, progress in immunotherapy, and creative drug delivery systems.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp

What are the Key Market Players in Systemic Aspergillosis And Systemic Candidiasis Market and How They’re Evolving?

Major companies operating in the systemic aspergillosis and systemic candidiasis market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A., GlaxoSmithKline PLC, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Matinas BioPharma Holdings Inc., Shionogi & Co. Ltd, Cipla Limited, Taj Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Cidara Therapeutics Inc., T2 Biosystems Inc., Sandoz International GmbH, Grupo Ferrer International S.A., Entasis Therapeutics Inc., F2G Ltd., Mycovia Pharmaceuticals Inc., ContraFect Corporation, Enzon Pharmaceutical Inc., Pacgen Life Science Corporation, Biosergen AS, N8 Medical LLC

What Are the Primary Growth Drivers in the Systemic Aspergillosis And Systemic Candidiasis Market?

The rise in fungal diseases is projected to fuel the expansion of the systemic aspergillosis and systemic candidiasis market. Fungal diseases are infections induced by fungi that can impact different parts of the body, leading to a range of symptoms and complications. These conditions encompass cutaneous skin infections, respiratory infections, and systemic infections. The treatments for these diseases consist of antifungal drugs like oral azoles, voriconazole, and liposomal amphotericin B. For example, Lancet, a globally respected medical journal based in London, reported in July 2024 that annual estimates suggest 6.5 million invasive fungal infections occur, leading to 3.8 million fatalities, with about 2.5 million of these deaths directly attributed to the infections. Hence, the upsurge in fungal disease prevalence is stimulating the growth of the systemic aspergillosis and systemic candidiasis market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12148&type=smp

What Are the Leading Segments in the Global Systemic Aspergillosis And Systemic Candidiasis Industry?

The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –

1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types

2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications

3) By End User: Clinic, Hospital, Other End Users

Subsegments:

1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole

2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection

3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis

4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines

5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents

What Are the Key Market Trends in the Systemic Aspergillosis And Systemic Candidiasis Industry?

In order to improve the efficacy of treatment and address the mounting issue of antifungal resistance, major firms involved in the systemic aspergillosis and systemic candidiasis markets are focusing on the creation of advanced products such as echinocandins. These are a type of antifungal medication that hampers the creation of ß-glucan, a crucial component of the fungal cell wall. In March 2023, for example, Cidara Therapeutics and Melinta Therapeutics, both biotechnology companies based in the US, gained approval from the US Food and Drug Administration (FDA) for REZZAYO (rezafungin for injection). This innovative echinocandin, which is administered once a week, is used to treat candidemia in adults who have few or no other treatment options. REZZAYO’s straightforward once-weekly dosage schedule simplifies treatment and promotes continuous care for patients suffering from invasive candidiasis. This is particularly advantageous in hospital environments where effectively treating these infections is crucial.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/systemic-aspergillosis-and-systemic-candidiasis-global-market-report

What Is the Regional Outlook for the Systemic Aspergillosis And Systemic Candidiasis Market?

North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12148

This Report Delivers Insight On:

1. How big is the systemic aspergillosis and systemic candidiasis market, and how is it changing globally?

2. Who are the major companies in the systemic aspergillosis and systemic candidiasis market, and how are they performing?

3. What are the key opportunities and risks in the systemic aspergillosis and systemic candidiasis market right now?

4. Which products or customer segments are growing the most in the systemic aspergillosis and systemic candidiasis market?

5. What factors are helping or slowing down the growth of the systemic aspergillosis and systemic candidiasis market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model